Precipio Announces Q3-2026 Financial Results

NEW HAVEN, Conn., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) (link) announces third-quarter financial results for the quarter ending September 30, 2026.

Below are some of the key financial performance metrics for the Company. For additional results, please see the Company’s Form 10-Q filed today. * Revenue – $7.3M, up 8% year-over-year from $6.8M in Q3-2025 and from $7.0M in Q2-2026. This comprises $1.0M in product revenue (up 40% year-over-year from $0.7M in Q3-2025, and $0.9M in Q2-2026), and $6.3M in pathology revenue (up 5% year-over-year from $6.0M in Q3-2025, and $6.1M in Q2-2026). * Adjusted EBITDA – $0.4M vs. $0.5M in Q3-2025 and $0.4M in Q2-2026. * Cash flow - Cash flow from operations was $0.6M in Q3-2026; total cash increased by $0.5M, resulting in an end-of-quarter cash balance exceeding $3.5M, vs $2.3M in Q3-2025. “In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations,” said Ilan Danieli, CEO of Precipio. “Our pathology business continues to provide a strong operational and financial foundation for growth, while also serving as the clinical development and validation platform for our proprietary diagnostic products. With more than $3.5 million in cash at quarter-end, we believe we are well positioned to accelerate commercialization of our existing product portfolio and pursue the significant longer-term growth opportunities ahead of us.”